Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hemoglobin Clear all

Conditions: Anemia in Incident Dialysis Patients
Interventions: Roxadustat, Epoetin Alfa; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 1,043 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Chula Vista, California • La Mesa, California • San Diego, California + 25 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tetrahydrobiopterin (BH4), Antioxidant Cocktail; Drug · Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Hemoglobin, Cerebral Oxygenation, Congenital Heart Disease
Interventions: Noninvasive hemoglobin monitoring; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 0 Days to 21 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Spine Surgery Procedure
Interventions: Masimo Radical-7; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: β-thalassemia Major
Interventions: LentiGlobin BB305 Drug Product; Genetic
Lead sponsor: Genetix Biotherapeutics Inc.; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 4
States / cities: Los Angeles, California • Oakland, California • Chicago, Illinois + 1 more

Conditions: Prescription Medication Understanding
Interventions: Enhanced Label; Other
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: Maridebart Cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 28
States / cities: Birmingham, Alabama • Anaheim, California • Canoga Park, California + 25 more

Conditions: Sickle Cell Disease, Hb-SS Disease With Vasoocclusive Pain, Hemoglobin SS Disease With Vasoocclusive Crisis, Other Sickle Cell Disease With Vaso-Occlusive Pain, Hemoglobin SS Disease With Crisis
Interventions: Abciximab, Placebo, Intravenous hydration, Ibuprofen, Parenteral narcotic, Incentive spirometry, Supplemental oxygen; Drug · Other
Lead sponsor: St. Louis University; Other
Eligibility: 5 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes, Type 1, Diabetes, Type 2, Foot Ulcer, Diabetic
Interventions: Bacitracin, AmeriGel®, Vitamin C; Drug · Dietary Supplement
Lead sponsor: Susan Hassenbein; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: HM11260C, liraglutide, Placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: CA, California

Conditions: Patients Undergoing Spine Surgery
Interventions: intermediate-acting digital nerve block; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sickle Cell Disease
Interventions: panobinostat; Drug
Lead sponsor: Abdullah Kutlar; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Hemoglobin Results
Interventions: Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor, Standard Laboratory Blood Draw and Hemoglobin Analysis; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 30 Days to 18 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Anemia, End Stage Renal Disease
Interventions: AKB-6548; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 16
States / cities: El Granada, California • Long Beach, California • San Dimas, California + 13 more

Conditions: Sickle Cell Anemia, Hemoglobinopathy, Thalassemia
Interventions: Campath -1H, Dilantin, Busulfan, Cyclophosphamide; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Day to 64 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Hemorrhage, Postpartum
Interventions: Blood Draw; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Blood Loss
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 2 Diabetes Mellitus, Hyperglycemia
Interventions: Diabetes Pathway; Other
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 21 Years to 75 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Sickle Cell Disease, Hemoglobin SC
Interventions: Busulfan, Campath 1H, Cyclophosphamide and MESNA; Drug · Biological
Lead sponsor: Tami D. John; Other
Eligibility: Up to 40 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Surgery
Interventions: Masimo Pulse CO-Oximeter; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Canagliflozin, Sitagliptin, Metformin immediate release; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 45
States / cities: Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Sitagliptin 100 mg, Canagliflozin 300 mg, Metformin, Sulphonylurea; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 85
States / cities: Mobile, Alabama • Goodyear, Arizona • Mesa, Arizona + 82 more

Conditions: Type 2 Diabetes Treated With Insulin
Interventions: Insulin glargine, NovoLog, Insulin Fiasp, Standard carbohydrate diet; Drug · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Rainbow Resposable Adhesive Sensors; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Irvine, California

Search by objective public record fields.

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)

Observational Data Collection for Blood Hemoglobin Algorithm Validation in Pediatrics

Masimo Radical-7 Monitor a Useful Adjuvant During Major Spine Surgery

A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

Enhanced Prescription Drug Label to Improve Patient Understanding and Use

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis

The Relationship of Hemoglobin A1c and Diabetic Wound Healing

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

The Influence of a Bupivacaine Digital Nerve Block Using Rev G.

Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

Comparing Validity of Non-Invasive Hemoglobin Monitoring to Laboratory Results in Critically Ill Children

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

Time of Postpartum Hemoglobin Assessment and Blood Loss During Delivery

Comparison of Three Methods of Hemoglobin Monitoring

MedStar Health Type 2 Diabetes Pathway to Control

Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP

Validation of Noninvasive Hemoglobin, Comparison of PVI to Standard Methods, and Validation of Clinical Efficacy of ORI

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

Accuracy of Noninvasive Hemoglobin Pulse Oximeter (Rainbow Resposable Adhesive Sensors)